Interagency Patent Coordination and Improvement Act of 2025
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Jul 21, 2025)
Interagency Patent Coordination and Improvement Act of 2025
This bill establishes the Interagency Task Force on Patents to support coordination and communication between the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) on activities relating to patents for human drugs and biological products.
The task force's duties shall include sharing information about (1) the processes of each agency, including how each agency evaluates applications (e.g., patent applications at the USPTO and new drug applications at the FDA); and (2) new approvals of patents, human drugs, biological products, and new technologies. The task force must also establish a process that requires (1) the USPTO to request from the FDA information relating to certain patent applications to help patent examiners carry out their duties, (2) the FDA to provide such information to the USPTO, and (3) the USPTO to assist the FDA in its ministerial role of listing patents.
What just happenedJul 21, 2025
Referred to the House Committee on the Judiciary.
Who’s behind it
- Introduced in HouseJul 21, 2025
- Jul 21, 2025IntroReferralH11100
Referred to the House Committee on the Judiciary.
- Jul 21, 2025IntroReferralIntro-H
Introduced in House
- Jul 21, 2025IntroReferral1000
Introduced in House